Baudax Bio (Baudax Bio) Additional Paid-In Capital : $178.94 Mil(As of Sep. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Baudax Bio Additional Paid-In Capital?

Baudax Bio's quarterly additional paid-in capital increased from Mar. 2023 ($172.16 Mil) to Jun. 2023 ($176.13 Mil) and increased from Jun. 2023 ($176.13 Mil) to Sep. 2023 ($178.94 Mil).

Baudax Bio's annual additional paid-in capital increased from Dec. 2020 ($97.03 Mil) to Dec. 2021 ($145.31 Mil) and increased from Dec. 2021 ($145.31 Mil) to Dec. 2022 ($166.65 Mil).

Baudax Bio Additional Paid-In Capital Historical Data

The historical data trend for Baudax Bio's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baudax Bio Additional Paid-In Capital Chart

Baudax Bio Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Additional Paid-In Capital

Get a 7-Day Free Trial

19.41

97.03

145.31

166.65

Baudax Bio Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Additional Paid-In Capital	Get a 7-Day Free Trial															161.91	166.65	172.16	176.13	178.94

Baudax Bio Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Baudax Bio Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Baudax Bio's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Baudax Bio (Baudax Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Baudax Bio Inc (OTCPK:BXRXQ) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

490 Lapp Road, Malvern, PA, USA, 19355

Website

https://www.baudaxbio.com

Baudax Bio Inc is a Pharmaceutical company. The company develops and commercialize products for hospital and related acute care settings. Its products are in pipeline which includes two novel neuromuscular blocking agents, or NMBAs.

Executives

Natalie Mcandrew	officer: Interim CFO	C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Yong Chan Kim	director	C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Winston J Churchill	director	C/O SCP PARTNERS, SUITE 300, 1200 LIBERTY RIDGE DRIVE, WAYNE PA 19087
William Ashton	director	C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Andrew T Drechsler	director	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Arnold M Baskies	director	1235 SEQUOIA ROAD, CHERRY HILL NJ 08003
Wayne Weisman	director	490 LAPP ROAD, MALVERN PA 19355
Jillian Dilmore	officer: Corporate Controller/Secretary, other: PFO and PAO	C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Geraldine Henwood	director, officer: President and CEO	88 SIDNEY ST, CAMBRIDGE MA 02139
Richard S Casten	officer: Chief Financial Officer	490 LAPP ROAD, MALVERN PA 19355
Alfred Altomari	director	C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
Ryan David Lake	director, officer: Chief Financial Officer	KENSEY NASH CORPORATION, 735 PENNSYLVANIA DRIVE, EXTON PA 19341
Recro Pharma, Inc.	10 percent owner	1 E. UWCHLAN AVE, SUITE 112, EXTON PA 19341